Tags

Type your tag names separated by a space and hit enter

A prospective randomized trial comparing somatostatin and sclerotherapy in the treatment of acute variceal bleeding.
Hepatology. 1994 Aug; 20(2):370-5.Hep

Abstract

Somatostatin and endoscopic sclerotherapy are widely used in the treatment of acute variceal bleeding. Although objective evidence does exist about the advantages of either treatment, data comparing both procedures are scarce. In order to compare the effectiveness and safety of somatostatin and sclerotherapy in the treatment of acute variceal bleeding, 70 consecutive cirrhotic patients suffering from esophageal variceal hemorrhage and meeting the inclusion criteria were randomly assigned to treatment with somatostatin (35 patients) or sclerotherapy (35 patients). No differences in age, sex, alcohol intake, etiology of cirrhosis and severity of liver failure were found between groups. Failure of treatment (defined as persistence of bleeding despite therapy or subsequent rebleeding within the 48-hr trial period) occurred in seven patients (20%) in the somatostatin group and in six (17.1%) in the sclerotherapy group (NS). Early rebleeding occurred in seven of 28 patients (25%) in the somatostatin group and in five of 29 (17.2%) in the sclerotherapy group (NS). Mortality within the first 6 wk was no different between both groups: 10 (28.5%) and eight (22.8%) in the somatostatin and sclerotherapy groups, respectively. Sclerotherapy, but not somatostatin, was associated with major complications in five cases (14.2%) (p = 0.026), two of which resulted in patient's death. These results suggest that somatostatin is safer, and as effective as sclerotherapy, in controlling acute variceal bleeding until an elective treatment can be established.

Authors+Show Affiliations

Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

7913907

Citation

Planas, R, et al. "A Prospective Randomized Trial Comparing Somatostatin and Sclerotherapy in the Treatment of Acute Variceal Bleeding." Hepatology (Baltimore, Md.), vol. 20, no. 2, 1994, pp. 370-5.
Planas R, Quer JC, Boix J, et al. A prospective randomized trial comparing somatostatin and sclerotherapy in the treatment of acute variceal bleeding. Hepatology. 1994;20(2):370-5.
Planas, R., Quer, J. C., Boix, J., Canet, J., Armengol, M., Cabre, E., Pintanel, T., Humbert, P., Oller, B., & Broggi, M. A. (1994). A prospective randomized trial comparing somatostatin and sclerotherapy in the treatment of acute variceal bleeding. Hepatology (Baltimore, Md.), 20(2), 370-5.
Planas R, et al. A Prospective Randomized Trial Comparing Somatostatin and Sclerotherapy in the Treatment of Acute Variceal Bleeding. Hepatology. 1994;20(2):370-5. PubMed PMID: 7913907.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A prospective randomized trial comparing somatostatin and sclerotherapy in the treatment of acute variceal bleeding. A1 - Planas,R, AU - Quer,J C, AU - Boix,J, AU - Canet,J, AU - Armengol,M, AU - Cabre,E, AU - Pintanel,T, AU - Humbert,P, AU - Oller,B, AU - Broggi,M A, PY - 1994/8/1/pubmed PY - 1994/8/1/medline PY - 1994/8/1/entrez SP - 370 EP - 5 JF - Hepatology (Baltimore, Md.) JO - Hepatology VL - 20 IS - 2 N2 - Somatostatin and endoscopic sclerotherapy are widely used in the treatment of acute variceal bleeding. Although objective evidence does exist about the advantages of either treatment, data comparing both procedures are scarce. In order to compare the effectiveness and safety of somatostatin and sclerotherapy in the treatment of acute variceal bleeding, 70 consecutive cirrhotic patients suffering from esophageal variceal hemorrhage and meeting the inclusion criteria were randomly assigned to treatment with somatostatin (35 patients) or sclerotherapy (35 patients). No differences in age, sex, alcohol intake, etiology of cirrhosis and severity of liver failure were found between groups. Failure of treatment (defined as persistence of bleeding despite therapy or subsequent rebleeding within the 48-hr trial period) occurred in seven patients (20%) in the somatostatin group and in six (17.1%) in the sclerotherapy group (NS). Early rebleeding occurred in seven of 28 patients (25%) in the somatostatin group and in five of 29 (17.2%) in the sclerotherapy group (NS). Mortality within the first 6 wk was no different between both groups: 10 (28.5%) and eight (22.8%) in the somatostatin and sclerotherapy groups, respectively. Sclerotherapy, but not somatostatin, was associated with major complications in five cases (14.2%) (p = 0.026), two of which resulted in patient's death. These results suggest that somatostatin is safer, and as effective as sclerotherapy, in controlling acute variceal bleeding until an elective treatment can be established. SN - 0270-9139 UR - https://www.unboundmedicine.com/medline/citation/7913907/A_prospective_randomized_trial_comparing_somatostatin_and_sclerotherapy_in_the_treatment_of_acute_variceal_bleeding_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0270-9139&date=1994&volume=20&issue=2&spage=370 DB - PRIME DP - Unbound Medicine ER -